Amidst of COVID-19 outbreak, Infinium wishes to extend its support to the industry by offering 30% discount on its market research reports across all license formats.
COVID-19! We are now including the impact analysis of the COVID-19 on Overactive Bladder Treatment Market report and the forecast period of this report shall be revised to 2020-2026. The section on the impact of COVID-19 on this market is included in the report for free. To know more Request a Sample of this report.

Overactive Bladder Treatment Market (Therapy Type - Anticholinergic, Solifenacin, Fesoterodine, Oxybutynin, Mirabegron, Darifenacin, Boto, and Neurostimulation; Disease Type - Idiopathic Bladder Overactivity, and Neurogenic Bladder Overactivity): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : July, 2019

  • Rep Id : HC0612

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on overactive bladder treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional overactive bladder treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional overactive bladder treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global overactive bladder treatment market. According to the report, the global overactive bladder treatment market is projected to grow at a CAGR of 3.1% over the forecast period of 2019-2025.


Market Insight

The global overactive bladder treatment market is expected to gain promising growth throughout the forecast period. Growing occurrence of overactive bladder (OAB) along with the growing geriatric population and increasing prevalence of chronic kidney disease (CKD) are the major factors promoting the growth of overactive bladder market. As per the National Association for continence, approximately, 33 million people have an overactive bladder in the USA alone, in 2016. Additionally, the growing development of innovative intravesical therapies is likely to contribute to market growth. However, low awareness of overactive bladder treatment among developing countries is expected to affect the growth of the overactive bladder treatment market. Furthermore, favorable reimbursements and a number of manufacturers are focusing on research and the development of novel drugs creates favorable growth opportunities for the overactive bladder treatment market.


Among the regions, the global overactive bladder treatment market is segmented into North America, Europe, Asia-Pacific, and RoW. North America is dominating the global overactive bladder treatment market. The U.S. dominated the market owing to the well-established healthcare industry. The factors such as growing elderly population, growing prevalence of chronic kidney disease (CKD), high incidences of urinary disorders and increasing number of drugs receiving the FDA approval are responsible for the market growth in North America. Europe is expected to hold the second position in the overactive bladder treatment market. This is due to the presence of favorable government policies regarding the development of health care infrastructure in the region.


Asia-Pacific is expected to be the fastest-growing region in this market throughout the forecast period. Additionally, the expansion of pharmaceutical companies and biotech labs in countries such as China and India have a positive impact on the market in the Asia-Pacific region. The growth in the geriatric population coupled with rising per capita health care expenditure is escalating the market in the Asia-Pacific region. The Middle East and Africa are anticipated to experience steady growth in the overactive bladder treatment market over the forecast period.


Segment Covered

The report on global overactive bladder treatment market covers segments such as therapy type, and disease type. On the basis of therapy type, the sub-markets include anticholinergic, solifenacin, fesoterodine, oxybutynin, mirabegron, darifenacin, boto, and neurostimulation. On the basis of disease type, the sub-markets include idiopathic bladder overactivity, and neurogenic bladder overactivity.


Companies Profiled:

The report provides profiles of the companies in the market such as Medtronic plc, Apotex Inc., Intas Biopharmaceuticals, Johnson & Johnson, Aurobindo Pharma Limited, Sanofi S.A., Hisamitsu Pharmaceutical Co., Inc., Endo International plc. Mylan N.V., Allergan plc. and other companies.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of overactive bladder treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount